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England’s National Chlamydia Screening Programme(NCSP) occupies a uniquely challenging place with-
in health policy. The UK National Screening
Committee, whose responsibility for setting screening
policy is recommended as a model for Europe,1 has not
been involved in initiating the NCSP. Its guidance
remains that chlamydia screening should not be offered
in pregnancy, and it describes the NCSP not as a screen-
ing programme, but as a ‘communicable disease con-
trol programme’.2 Its most recent review in 2002 did
not recommend general population screening for
chlamydia.
This presents a challenge to the NCSP rollout, in the
risk of being cut adrift from the mainstream of screening
policy and practice in the UK, and from a wealth of expe-
rience in the development and management of sustain-
able screening programmes. The management of the
NCSP is also unique among screening programmes in
being managed by the Health Protection Agency, an
‘arms-length’ body that has limited direct control over, or
accountability for, NHS outcomes or practice,3 and that
does not manage any of the other existing large-scale
screening programmes. 
Is opportunistic screening effective?
This comes at a time when reviews of recent evidence
have cast doubt on the evidence base for the current
approach to chlamydia screening. ‘Proactive’ models of
screening use population registers to identify a target
population, and invite people personally to partici-
pate.1,4 This is the overarching strategy used for pro-
grammes approved by the National Screening
Committee. ‘Opportunistic’ screening involves offering
tests to people already attending healthcare settings.1,4
A rapid review of evidence commissioned by the
National Institute for Health and Clinical Excellence
reported that the evidence from randomised controlled 
trials is limited to the impact of register-based (‘proac-
tive’) screening on the incidence of pelvic inflammato-
ry disease, while there are no trials of the impact of
‘opportunistic’ screening in the general population.4
Recent evidence from a large Scandinavian cohort
study suggests that the rate of progression to pelvic
inflammatory disease, ectopic pregnancy and infertility
may be lower than estimated in earlier work based in
secondary care.5
So, what do we know about the effectiveness of the
opportunistic model of chlamydia screening that is now
being rolled out by the NCSP? The programme is in
some respects based on the model used in the original
pilots, which assessed the feasibility and acceptability of
an opportunistic approach to a single round of screen-
ing.6,7 The need for pilots of social and healthcare
interventions is increasingly recognised in the UK.8
However, this ‘pilot’ was in effect a blueprint for imple-
mentation, and, as such, had significant flaws according
to the wider evidence on the prerequisites for a screen-
ing programme. 
It is well established that organised programmes of
screening require for their success that individual
women are identifiable, and that specific measures (such
as letters of invitation) are necessary in order to ensure
high coverage.9,10 This was a lesson learned early in cer-
vical screening, which resulted in a move from oppor-
tunistic to register-based screening, to maximise uptake
among vulnerable groups. However, the chlamydia pilots
were not designed to determine the feasibility of 
repeated rounds of screening, nor were they capable of
providing a model for the monitoring, evaluation and
improvement of any high-coverage screening pro-
gramme. Modelling work, however, confirms that 
coverage of at least 50 per cent of the target population
will be central to success.11
Uptake was estimated without specific reference to
the GP-registered population forming the basis for the
established screening programmes for cervical and
breast cancer, and, most importantly, for identifying
groups and localities with poor uptake. Current 
performance indicators still do not specify the GP-
registered population (as opposed to attenders) as a
contributor to the denominator against which perform-
ance in meeting local delivery plan targets can be meas-
ured.12 Proper attention to the challenges of measuring
uptake, and, in particular, to the identification of
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groups at risk of low uptake and developing means of
reaching them, is an essential task if good coverage is to
be achieved. This will require use of the apparatus that
has made other forms of screening in the UK a success. 
Increasing coverage through primary care registers
Many observers saw the most successful element of the
original pilots as the large-scale engagement of primary
care,6,7 yet the relative lack of primary care involvement
is the most striking difference between the pilots and
the existing NCSP, with only 15.4 per cent of non-geni-
tourinary medicine screens in 2005/06 coming from
primary care.3 In the Portsmouth chlamydia screening
pilot,6,7 83 per cent of 79 local practices took part in
screening throughout the year, with 62.9 per cent of
11 999 tests and 61 per cent of all positives coming from
primary care, with a positivity of 9.1 per cent. Each year,
60.4 per cent of men and 75.3 per cent of women aged
16–24 years attend their GP practice at least once, and
within a year 21.3 per cent would be reached only by
post, 9.2 per cent would not receive a letter but would
attend, and 11.8 per cent would be missed by both
methods.13 These data, from a study aiming to compare
the potential coverage of opportunistic with register-
based screening, suggest that supplementing existing
strategies by invitation through primary care registers is
the only approach likely to achieve high coverage. 
Identification of high-risk groups
The NCSP is undertaking a major extension of activity
into other settings, which were not evaluated in the orig-
inal pilots. These include universities, colleges and
schools, from which 9.6 per cent of 96 890 screens origi-
nated in 2005/06, along with a further 4.2 per cent from
undefined ‘other’ settings. A separate commissioning of
testing through a chain of commercial pharmacies has
also taken place. This is, as the NCSP group describes it,
‘proactive’ but not register-based screening,14 and it
presents a challenge for the measurement of outcomes
and, most importantly, the identification of high-risk
groups with poor uptake. The identification of groups at
risk of poor uptake of screening is an essential part of the
evaluation of a screening programme, which cannot be
postponed indefinitely. The local delivery plan target for
2007/08 is 15 per cent of the estimated total population
aged 15–24 years. 
In order for the NCSP to achieve maximum benefit
and efficiency, it will be important to ensure wider and
repeated coverage, but to minimise repeated coverage of
the lowest-risk individuals who may well be the easiest to
access. Without the use of registers – by contrast with all
other screening programmes – a large, long-term
unscreened group will be the likely result, as in the early
days of cervical screening. The NCSP’s increasing focus
on accessible social venues is as yet unevaluated in popu-
lation terms, but could result in annual testing of large
numbers of university students, while less well-off adoles-
cents in rural or otherwise isolated areas may be at risk
of receiving no screening offers. Determining the
NCSP’s impact on health inequalities will require fine-
grain locality-based uptake measures.
The engagement of primary care in the chlamydia
screening pilots was made possible by financial incen-
tives in the form of a £25 payment for the first 600 tests
and £10 thereafter.7 This aspect of incentivisation is, on
the whole, regarded with nervousness by genitourinary
medicine and family planning clinicians, who are
salaried practitioners. However, capitation and incen-
tives (now in the form of the quality and outcomes
framework) have always been fundamental to how pri-
mary care identifies the personnel and equipment
resources for its tasks. Without harnessing primary care
across the country, it is difficult to see how high cover-
age can be achieved – the NHS in Cornwall and the
Scilly Isles is alone in achieving coverage of an estimat-
ed 15–19 per cent of the sexually active 15- to 24-year-
old population over a large geographic area.3 It has
notably done this by engaging 85 per cent of GP prac-
tices in addition to other healthcare settings, and pro-
viding free azithromycin for the treatment of positive
patients in the practice setting. 
Coverage of men will need special attention. In spite of
evidence that large numbers of men do indeed attend pri-
mary care with genital symptoms,15 testing rates for
chlamydia are extremely low.16 Many programme areas of
the NCSP are focussing on non-healthcare settings with a
view to recruiting young men. However, the cost-effective-
ness of such an approach – by contrast with using the pri-
mary care setting as a focus of testing and targeting – is
unproven.
If the NCSP is to achieve its aim of reducing morbidity
as a result of chlamydia, it must be supported in develop-
ing an approach to screening that will allow detailed meas-
urement of uptake and monitoring of screening intervals,
and, importantly, show what inequalities of access it needs
to address as the programme grows. This will require co-
ordination with other screening programmes, and the
practical support of leaders of other existing, highly suc-
cessful programmes.
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